Zhejiang Huakang Pharmaceutical Co., Ltd.
SSE:605077.SS
15.09 (CNY) • At close April 30, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,808.436 | 2,782.696 | 2,200.023 | 1,594.016 | 1,319.652 | 1,510.856 | 1,399.743 | 924.633 | 763.338 |
| Cost of Revenue
| 2,197.004 | 2,109.774 | 1,695.339 | 1,226.885 | 858.181 | 999.412 | 1,021.209 | 698.041 | 600.838 |
| Gross Profit
| 611.432 | 672.921 | 504.684 | 367.131 | 461.472 | 511.444 | 378.533 | 226.593 | 162.5 |
| Gross Profit Ratio
| 0.218 | 0.242 | 0.229 | 0.23 | 0.35 | 0.339 | 0.27 | 0.245 | 0.213 |
| Reseach & Development Expenses
| 128.409 | 124.276 | 99.713 | 84.229 | 65.034 | 53.795 | 43.919 | 28.119 | 21.654 |
| General & Administrative Expenses
| 46.478 | 24.891 | 22.444 | 20.712 | 17.55 | 17.368 | 13.89 | 13.616 | 37.829 |
| Selling & Marketing Expenses
| 28.696 | 23.008 | 35.804 | 27.761 | 18.443 | 104.789 | 74.322 | 68.876 | 45.577 |
| SG&A
| 75.174 | 127.855 | 58.248 | 48.473 | 35.993 | 122.157 | 88.212 | 82.492 | 83.406 |
| Other Expenses
| 118.504 | -7.397 | 39.416 | 23.382 | 14.625 | 39.135 | -0.03 | 1.287 | 2.739 |
| Operating Expenses
| 322.087 | 245.833 | 197.376 | 156.085 | 115.652 | 215.088 | 160.159 | 142.551 | 110.46 |
| Operating Income
| 289.345 | 427.088 | 349.231 | 256.644 | 356.115 | 310.531 | 224.308 | 62.804 | 31.107 |
| Operating Income Ratio
| 0.103 | 0.153 | 0.159 | 0.161 | 0.27 | 0.206 | 0.16 | 0.068 | 0.041 |
| Total Other Income Expenses Net
| -2.777 | -4.685 | -6.449 | -2.574 | -7.597 | -2.48 | 0.329 | 1.287 | 2.739 |
| Income Before Tax
| 286.567 | 422.403 | 342.782 | 254.07 | 348.518 | 308.051 | 224.637 | 64.091 | 33.845 |
| Income Before Tax Ratio
| 0.102 | 0.152 | 0.156 | 0.159 | 0.264 | 0.204 | 0.16 | 0.069 | 0.044 |
| Income Tax Expense
| 17.778 | 50.019 | 23.504 | 17.361 | 41.351 | 37.937 | 25.259 | 8.162 | 5.141 |
| Net Income
| 268.484 | 371.452 | 319.278 | 236.709 | 307.167 | 270.114 | 199.379 | 55.94 | 28.711 |
| Net Income Ratio
| 0.096 | 0.133 | 0.145 | 0.148 | 0.233 | 0.179 | 0.142 | 0.06 | 0.038 |
| EPS
| 0.9 | 1.63 | 1.4 | 1.04 | 1.34 | 1.18 | 1.21 | 0.38 | 0.19 |
| EPS Diluted
| 0.71 | 1.63 | 1.4 | 1.04 | 1.34 | 1.18 | 1.21 | 0.38 | 0.19 |
| EBITDA
| 525.744 | 630.763 | 463.496 | 343.188 | 415.654 | 350.53 | 275.692 | 124.646 | 102.809 |
| EBITDA Ratio
| 0.187 | 0.227 | 0.211 | 0.215 | 0.315 | 0.232 | 0.197 | 0.135 | 0.135 |